WALTHAM, Mass. , June 12 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2008, ended March 31, 2008 . Total revenue for fiscal year 2008 was $19,296,000 compared to total revenue of $14,074,000 for fiscal year 2007 ended March 31, 2007 , an increase of $5,222,000 or 37%. Total revenue for the year consisted primarily of Protein A and SecreFlo(R) product revenue.
Operating expenses for fiscal year 2008, excluding the $40,170,000 net gain from litigation previously reported in our second quarter as a result of our settlement with ImClone Systems, Inc., were $23,574,000 compared to $15,900,000 in fiscal year 2007. The increase in operating expenses of $7,674,000 was primarily the result of legal expenses incurred in conjunction with both the ImClone Systems, Inc. and Bristol-Myers Squibb litigations, direct material expenses associated with the increase in revenue, and increased research and development spending.
Net income for the year was $37,107,000 or $1.18 per diluted share, compared to a net loss for fiscal 2007 of $889,000 or $0.03 per diluted share. Net income includes a net gain of $40,170,000 from the litigation settlement with ImClone during the second quarter of fiscal year 2008. Cash and marketable securities as of March 31, 2008 were $60,589,000 compared to $22,627,000 as of March 31, 2007 .
'During the past year, we have successfully advanced our product pipeline,
achieved strong revenue growth and settled our outstanding litigations with
ImClone Systems, Inc. and Bristol-Myers Squibb, resulting in substantial new
resources for the company,' stated
Total revenue for the fourth quarter of fiscal year 2008 was $3,301,000 compared to $3,699,000 for the same period in fiscal year 2007, a decrease of 11%. Operating expenses for the fourth quarter of fiscal year 2008 were $7,165,000 compared to $4,050,000 . Net loss for the fourth quarter of fiscal year 2008 was $3,198,000 or $0.10 per diluted share, compared to a net loss for the fourth quarter of fiscal year 2007 of $107,000 or $0.00 per diluted share.
Corporate Update
Secretin (RG1068) for Imaging of the Pancreas
In March, we initiated a Phase 3 clinical trial to evaluate the use of RG1068, synthetic human secretin, to improve the assessment of pancreatic duct structures by magnetic resonance imaging (MRI). The Phase 3 study is a multi-center, baseline-controlled, single dose study in which approximately 250 patients will receive an unenhanced MRI followed by a secretin-enhanced MRI of the pancreas. The study is designed to assess the sensitivity and specificity of secretin-enhanced MRI to improve the ability to detect pancreatic duct abnormalities relative to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the assessment, diagnosis and treatment of diseases such as acute and chronic pancreatitis. The study is being conducted at approximately 30 clinical sites within the United States and Canada . In April, the U.S. Food and Drug Administration granted Fast Track Designation to our development program. Fast Track is a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need.
Uridine (RG2417) for Bipolar Disorder
Today, we announced that based on feedback from the Food and Drug
Administration (FDA) we plan to initiate a Phase 2b clinical trial of RG2417,
an oral formulation of uridine in patients with bipolar disorder in the fall.
This will be a multi-center, parallel arm placebo-controlled, clinical trial
in which approximately 150 patients with bipolar disorder will receive either
RG2417 or a placebo twice a day for eight-weeks. This study is designed to
assess the efficacy and safety of RG2417 on the symptom of depression as
measured by the Montgomery-Asberg Depression Rating Scale (MADRS).
In addition, we announced today that we have completed our assessment of the data from the previous Phase 2a study and have found that patients with a history of more frequent symptoms demonstrated greater improvements when treated with RG2417 than patients without a history of frequent symptoms. For example, patients with more than 5 episodes of depression over their entire life (n=50) demonstrated greater improvements in their symptoms of depression compared to patients with 5 or fewer lifetime episodes of depression. From weeks 2-6 of treatment, the patients with more than 5 lifetime episodes of depression who received RG2417 had an average improvement on MADRS of 5.5 points over placebo (p<0.001), compared to all patients in the study receiving RG2417 who had an average improvement on MADRS of 3.0 points over placebo (p=0.01) as previously reported. This result may reflect the difficulty in accurate ly diagnosing bipolar disorder in the absence of frequent symptomatology and will be used in the design and execution of the next study.
HDAC Inhibitors for Friedreich's Ataxia
We are currently developing compounds which may have utility in treating Friedreich's ataxia. Over the past year, we made significant progress in identifying advanced leads through multiple rounds of novel compound library synthesis and screening for potency, specificity, metabolism and pharmacology. Over the next year these advanced leads will be further characterized in animal models for their pharmacologic, toxicologic and pharmacodynamic profiles to identify an appropriate candidate for the clinic. We have also received a grant from Go FAR to develop a biomarker tool which may be useful in monitoring the biochemical activity and guiding the dosing frequency of a clinical candidate in patients. Go FAR (Friedreich's Ataxia Research) is a fundraising organization headquartered in Turin, Italy formed by the non-profit group RUDI Onlus Committee, dedicated to raising donations to fund research and development of treatments for Friedreich's ataxia.
Intellectual Property
CTLA4-Ig Patent
In April, we reached a settlement with Bristol-Myers Squibb Company ( Bristol ) in our lawsuit alleging infringement of U.S. Patent No. 6,685,941, based on Bristol's sale of Orencia(R) for the treatment of rheumatoid arthritis. The settlement provided for Bristol to make an initial payment of $5,000,000 and to pay royalties on the U.S. net sales of Orencia(R) for any clinical indication at a rate of 1.8% for the first $500,000,000 of annual net sales, 2.0% for the next $500,000,000 of annual net sales and 4% of annual net sales in excess of $1 billion for each year until December 31, 2013 . Based on analysts' estimates for the future U.S. sales of Orencia(R), we anticipate cash receipts in excess of $100 million over the term of the license.
Quarterly Conference Call
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com.
REPLIGEN CORPORATION
STATEMENTS OF OPERATIONS
(Unaudited)
Three months ended Year ended
March 31, March 31,
2008 2007 2008 2007
Revenue:
Product revenue $3,136,577 $3,396,737 $18,587,376 $13,073,894
Other revenue 164,200 302,075 708,905 1,000,345
Total revenue 3,300,777 3,698,812 19,296,281 14,074,239
Operating expenses:
Cost of product
revenue 1,303,054 901,952 6,160,245 3,614,837
Research and
development 2,357,696 1,452,215 7,240,812 5,924,439
Selling,
general and
administrative 3,504,362 1,695,945 10,173,400 6,360,292
Net gain from
litigation
settlement - - (40,170,000) -
Total operating
expenses 7,165,112 4,050,112 (16,595,543) 15,899,568
Income (loss) from
operations (3,864,335) (351,300) 35,891,824 (1,825,329)
Investment income 668,480 246,782 2,051,258 947,547
Interest expense (1,744) (2,451) (9,097) (11,481)
Income (loss) before
income taxes (3,197,599) (106,969) 37,933,985 (889,263)
Provision for
income taxes - - (827,471) -
Net income (loss) $(3,197,599) $(106,969) $37,106,514 $(889,263)
Earnings (loss)
per share:
Basic $(0.10) $- $1.20 $(0.03)
Diluted $(0.10) $- $1.18 $(0.03)
Weighted average
shares outstanding:
Basic 31,064,483 30,419,879 30,834,491 30,379,350
Diluted 31,064,483 30,419,879 31,320,997 30,379,350
As of March 31,
(In thousands)
Unaudited
Balance Sheet Data: 2008 2007
Cash and marketable securities* $60,589 $22,627
Working capital 49,831 22,394
Total assets 68,840 29,076
Long-term obligations 143 200
Accumulated deficit (120,577) (157,683)
Stockholders' equity 64,107 25,538
*does not include restricted cash
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.
SOURCE Repligen Corporation
